We are excited to announce that SHIFTBIO INC. has been chosen to join President Yoon Suk-yeol's business delegation to the United States. As a leading innovative startup in South Korea, we are dedicated to expanding our market presence and fostering collaboration in advanced industries between the two nations, in line with the delegation's 'cutting-edge industry' theme.
The business delegation has drawn significant attention, featuring four major group leaders and six heads of economic organization. A total of 122 entities, including large corporations, SMEs, industry associations, and public institutions, are taking part, making it the largest delegation since President Yoon's inauguration. Notably, 14 pharmaceutical and biotech firms, as well as seven digital healthcare companies, make up 17.2% of the delegation, underscoring the current administration's commitment to the biohealth sector.
Together with other delegation members, SHIFTBIO will not only engage in discussions on economic and industrial collaboration between South Korea and the US but also build a platform for networking opportunities with US government officials and business leaders, paving the way for future growth.
Read more about the delegation here:
https://www.koreabiomed.com/news/articleView.html?idxno=20935
We are excited to announce that SHIFTBIO INC. has been chosen to join President Yoon Suk-yeol's business delegation to the United States. As a leading innovative startup in South Korea, we are dedicated to expanding our market presence and fostering collaboration in advanced industries between the two nations, in line with the delegation's 'cutting-edge industry' theme.
The business delegation has drawn significant attention, featuring four major group leaders and six heads of economic organization. A total of 122 entities, including large corporations, SMEs, industry associations, and public institutions, are taking part, making it the largest delegation since President Yoon's inauguration. Notably, 14 pharmaceutical and biotech firms, as well as seven digital healthcare companies, make up 17.2% of the delegation, underscoring the current administration's commitment to the biohealth sector.
Together with other delegation members, SHIFTBIO will not only engage in discussions on economic and industrial collaboration between South Korea and the US but also build a platform for networking opportunities with US government officials and business leaders, paving the way for future growth.
Read more about the delegation here:
https://www.koreabiomed.com/news/articleView.html?idxno=20935